Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.
Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, Yamamoto K; Okayama Liver Cancer Group. Miyahara K, et al. Among authors: iwadou s. Br J Cancer. 2013 Oct 15;109(8):2072-8. doi: 10.1038/bjc.2013.554. Epub 2013 Sep 17. Br J Cancer. 2013. PMID: 24045661 Free PMC article.
Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma.
Oyama A, Nouso K, Yoshimura K, Morimoto Y, Nakamura S, Onishi H, Takaki A, Iwadou S, Kariyama K, Kuwaki K, Yabushita K, Sakaguchi K, Toshimori J, Kobashi H, Moriya A, Ando M, Okada H; Okayama Hepatocellular Carcinoma Study Group. Oyama A, et al. Among authors: iwadou s. Hepatol Res. 2021 Jun;51(6):694-701. doi: 10.1111/hepr.13633. Epub 2021 Mar 29. Hepatol Res. 2021. PMID: 33687130
Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial.
Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y. Kudo M, et al. Among authors: iwadou s. Liver Cancer. 2019 Nov;8(6):505-519. doi: 10.1159/000503032. Epub 2019 Oct 8. Liver Cancer. 2019. PMID: 31799207 Free PMC article.
Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib.
Adachi T, Nouso K, Miyahara K, Oyama A, Wada N, Dohi C, Takeuchi Y, Yasunaka T, Onishi H, Ikeda F, Nakamura S, Shiraha H, Takaki A, Takabatake H, Fujioka SI, Kobashi H, Takuma Y, Iwadou S, Uematsu S, Takaguchi K, Hagihara H, Okada H; Okayama Liver Cancer Group. Adachi T, et al. Among authors: iwadou s. J Gastroenterol Hepatol. 2019 Jun;34(6):1081-1087. doi: 10.1111/jgh.14535. Epub 2018 Dec 10. J Gastroenterol Hepatol. 2019. PMID: 30402928
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, Iwadou S, Horiguchi S, Takahashi H, Suzuki E, Moriguchi M, Tsuji K, Otsuka T, Asagi A, Kojima Y, Takada R, Morizane C, Mizuno N, Ikeda M, Ueno M, Furuse J. Kobayashi S, et al. Among authors: iwadou s. Cancer Sci. 2018 Aug;109(8):2549-2557. doi: 10.1111/cas.13656. Epub 2018 Jun 27. Cancer Sci. 2018. PMID: 29856900 Free PMC article.
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Kudo M, et al. Among authors: iwadou s. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7. Lancet Gastroenterol Hepatol. 2018. PMID: 29631810 Clinical Trial.
Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma.
Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Iwadou S, Kobayashi Y, Takaguchi K, Takuma Y, Takabatake H, Sakaguchi K, Yamamoto K; Okayama Liver Cancer Group. Miyahara K, et al. Among authors: iwadou s. Hepatol Res. 2014 Mar;44(3):296-301. doi: 10.1111/hepr.12123. Epub 2013 Apr 29. Hepatol Res. 2014. PMID: 23607549
15 results